Arcutis Biotherapeutics, Inc. vs UnitedHealth Group Incorporated — Stock Comparison
Arcutis Biotherapeutics, Inc. (ARQT) and UnitedHealth Group Incorporated (UNH) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Arcutis Biotherapeutics, Inc. narrowly edges UnitedHealth Group Incorporated on Q·Score (6.7 vs 6.1 out of 10), led by Growth (7.7 vs 5.1) and Health (7.4 vs 5.3). UnitedHealth Group Incorporated scores higher on Quality, reflecting stronger profitability and returns. Analyst consensus targets imply greater upside for ARQT (+32.1%) than for UNH (+2.2%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
Consensus analyst target of $34.63 is 32% above current price.
⚠ currently unprofitable (-1% margin).
82% of 28 covering analysts have a positive rating.
⚠ limited growth momentum.
Analyst Consensus
Fundamentals
Frequently Asked Questions
ARQT vs UNH: which stock scores better overall?
Based on Q·Score, Arcutis Biotherapeutics, Inc. (ARQT) scores 6.7/10 versus UnitedHealth Group Incorporated (UNH) at 6.1/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: ARQT or UNH?
Arcutis Biotherapeutics, Inc. (ARQT) scores higher on Growth (7.7/10 vs 5.1/10). Arcutis Biotherapeutics, Inc. reports revenue growth (60.1% YoY) while UnitedHealth Group Incorporated reports (2.0% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is ARQT or UNH more attractively valued?
Arcutis Biotherapeutics, Inc. (ARQT) scores higher on Valuation (8.1/10 vs 6.5/10). ARQT trades at 22.7× P/E versus UNH at 19.2×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about ARQT vs UNH?
There are 8 analysts covering ARQT with a consensus price target of $34.63, and 26 analysts covering UNH with a consensus target of $409.77. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: ARQT or UNH?
UnitedHealth Group Incorporated (UNH) scores higher on Quality (5.9/10 vs 3.5/10). Net profit margin: ARQT at -0.6%, UNH at 2.7%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: ARQT or UNH?
Arcutis Biotherapeutics, Inc. (ARQT) scores higher on Financial Health (7.4/10 vs 5.3/10). Market beta: ARQT at 1.52, UNH at 0.65. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of ARQT and UNH?
Arcutis Biotherapeutics, Inc. (ARQT) has a market capitalisation of $3.3B, while UnitedHealth Group Incorporated (UNH) has a market cap of $364.1B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →